2005Congestive Heart FailureOpen access

The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure

Imran Saleem Virk, John R. Ip

Open full text 8 citations

Abstract

Background.Cardiac resynchronization reduces symptoms and improves left ventricular function in many patients with heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony.We evaluated its effects on morbidity and mortality. Methods.Patients with New York Heart Association class III or IV heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony who were receiving standard pharmacologic therapy were randomly assigned to receive medical therapy alone or with cardiac resynchronization.The primary end point was the time to death from any cause or an unplanned hospitalization for a major cardiovascular event.The principal secondary end point was death from any cause. Results.A total of 813 patients were enrolled and followed for a mean of 29.4 months.The primary end point was reached by 159 patients in the cardiac resynchronization group, as compared with 224 patients in the medical therapy group (39% vs. 55%; hazard ratio, 0.63; 95% confidence interval [CI], 0.51-0.77;p<0.001).There were 82 deaths in the cardiac resynchronization group, as compared with 120 in the medical therapy group (20% vs. 30%; hazard ratio 0.64; 95% CI, 0.48-0.85;p<0.002).As compared with medical therapy, cardiac resynchronization reduced the interventricular mechanical delay, the

Open-access reader

About this research paper

What this paper is about

Background.Cardiac resynchronization reduces symptoms and improves left ventricular function in many patients with heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony.We evaluated its effects on morbidity and mortality. Methods.Patients with New York Heart Association class III or IV heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony who were receiving standard pharmacologic therapy were randomly assigned to receive medical therapy alone or with cardiac resynchronization.The primary end point was the time to death from any cause or an unplanned hospitalization for a major cardiovascular event.The principal secondary end point was death from any cause. Results.A total of 813 patients were enrolled and followed for a mean of 29.4 months.The primary end point was reached by 159 patients in the cardiac resynchronization group, as compared with 224 patients in the medical therapy group (39% vs. 55%; hazard ratio, 0.63; 95% confidence interval [CI], 0.51-0.77;p<0.001).There were 82 deaths in the cardiac resynchronization group, as compared with 120 in the medical therapy group (20% vs. 30%; hazard ratio 0.64; 95% CI, 0.48-0.85;p<0.002).As compared with medical therapy, cardiac resynchronization reduced the interventricular mechanical delay, the

Why it matters

OpenAlex reports 8 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Background.Cardiac resynchronization reduces symptoms and improves left ventricular function in many patients with heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony.We evaluated its effects on morbidity and mortality. Methods.Patients with New York Heart Association class III or IV heart failure due to left ventricular systolic dysfunction and cardiac dyssynchrony who were receiving standard pharmacologic therapy were randomly assigned to receive medical therapy alone or with cardiac resynchronization.The primary end point was the time to death from any cause or an unplanned hospitalization for a major cardiovascular event.The principal secondary end point was death from any cause. Results.A total of 813 patients were enrolled and followed for a mean of 29.4 months.The primary end point was reached by 159 patients in the cardiac resynchronization group, as compared with 224 patients in the medical therapy group (39% vs. 55%; hazard ratio, 0.63; 95% confidence interval [CI], 0.51-0.77;p<0.001).There were 82 deaths in the cardiac resynchronization group, as compared with 120 in the medical therapy group (20% vs. 30%; hazard ratio 0.64; 95% CI, 0.48-0.85;p<0.002).As compared with medical therapy, cardiac resynchronization reduced the interventricular mechanical delay, the

Key concepts: Medicine, Cardiac resynchronization therapy, Heart failure, Cardiology, Internal medicine, Hazard ratio, Ejection fraction, Ventricular dyssynchrony

Related papers

Back to paper searchBrowse research topicsOriginal source
The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure — Research Paper | ScholarLens